QIAGEN reports full results for second quarter and first half of 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Qiagen (QGEN) Reports In-Line Q2 EPS; Offers FY19 EPS Outlook
July 30, 2019 4:13 PM EDTQiagen (NYSE: QGEN) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $381.6 million versus the consensus estimate of $382.2 million.
QIAGEN delivers on Q2 2019 outlook (unchanged from July 24 announcement)Net sales of $381.6 million (+1% actual, +5% at constant exchange rates, or CER vs. ~5% CER outlook)Diluted EPS of $0.19; adjusted EPS $0.33 ($0.34 CER vs. ~$0.33-0.34 CER outlook)Sample to Insight portfolio developmentsQuantiFERON-TB up 6% CER in line with outlook, on track for >15% CER growthTwo FDA approvals to date in 2019 for novel therascreen companion... More